Chemotherapy with or without PD-1 antibody for advanced lung cancer patients with RET fusion
Chemotherapy or Chemotherapy Plus PD-1 Antibody in RET Fusion Positive Advanced Non-small Cell Lung Cancer ( Poseidon Study）
This study is testing if adding a PD-1 antibody to chemotherapy helps people with advanced lung cancer who have a specific gene change feel better and live longer.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 70 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Hunan Province Tumor Hospital Academic / other |
| Drugs / interventions | Chemotherapy |
| Locations | 1 site (Changsha, Hunan) |
| Trial ID | NCT04322591 on ClinicalTrials.gov |
What this trial studies
This study investigates the effectiveness and safety of chemotherapy alone or in combination with a PD-1 antibody for patients with RET Fusion Positive Advanced Non-small Cell Lung Cancer. It aims to enroll 100 patients and focuses on progression-free survival as the primary endpoint. The study is observational and will assess the outcomes of these treatment approaches in a real-world setting.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older with advanced non-squamous non-small cell lung cancer confirmed by histopathology and who are RET fusion positive.
Not a fit: Patients who have previously received antitumor treatment or have contraindications to chemotherapy may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide new treatment options that improve outcomes for patients with RET Fusion Positive Advanced Non-small Cell Lung Cancer.
How similar studies have performed: Other studies have shown promising results with similar approaches, particularly in targeting RET fusions in lung cancer, indicating potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * ≥18，Advanced Non-squamous Non-small Cell Lung Cancer Confirmed by Histopathology * RET Fusion Positive * First Diagnosis and Treatment * Treatment Plan is Chemotherapy or Chemotherapy plus PD-1 antibody Exclusion Criteria: * - Patients received antitumor treatment before * Patients with contraindication of chemotherapy * Pregnant or breast feeding women
Where this trial is running
Changsha, Hunan
- Yongchang Zhang — Changsha, Hunan, China (Recruiting)
Study contacts
- Principal investigator: Yongchang Zhang, MD — Hunan Cancer Hospital
- Study coordinator: Yongchang Zhang, MD
- Email: zhangyongchang@csu.edu.cn
- Phone: +8613873123436
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.